Cargando…
An overview of available drugs for management of opioid abuse during pregnancy
The prevalence of opioid abuse in the United States has been steadily increasing over the last several years among many major demographics, including pregnant women. Rise in prenatal opioid abuse has resulted in subsequent escalation of neonatal abstinence syndrome incidence, prompting the US Congre...
Autores principales: | , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5303227/ https://www.ncbi.nlm.nih.gov/pubmed/28203387 http://dx.doi.org/10.1186/s40748-017-0044-2 |
_version_ | 1782506669115179008 |
---|---|
author | Laslo, Jillian Brunner, Jon-Michael Burns, Daniel Butler, Emily Cunningham, Autumn Killpack, Ryan Pyeritz, Courtney Rinard, Kimberly Childers, Jennifer Horzempa, Joseph |
author_facet | Laslo, Jillian Brunner, Jon-Michael Burns, Daniel Butler, Emily Cunningham, Autumn Killpack, Ryan Pyeritz, Courtney Rinard, Kimberly Childers, Jennifer Horzempa, Joseph |
author_sort | Laslo, Jillian |
collection | PubMed |
description | The prevalence of opioid abuse in the United States has been steadily increasing over the last several years among many major demographics, including pregnant women. Rise in prenatal opioid abuse has resulted in subsequent escalation of neonatal abstinence syndrome incidence, prompting the US Congress to pass the Protecting Our Infants Act of 2015. This act specifically calls for a critical review of current treatment options for prenatal opioid abuse which may ultimately lead to the development of better therapies and a decreased incidence of neonatal abstinence syndrome. Currently, the American College of Obstetricians and Gynecologists recommends methadone, buprenorphine, or buprenorphine/naloxone in the treatment of prenatal opioid abuse. In this review, each maintenance therapy treatment option is discussed and compared revealing inconsistencies in postpartum retention rates, effects on fetal development, and availability to patients due to restrictions in health care coverage. Although each of these treatment options reduces opioid abuse and potential negative outcomes for the fetus, the shortcomings of these drugs highlight the overarching need for an improved standard of care. Drug developers and lawmakers should consider that affordability, coverage by health insurance, and success in retention rates substantially impacts the decision of the patient and healthcare provider regarding utilization of a particular opioid maintenance therapy. |
format | Online Article Text |
id | pubmed-5303227 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2017 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-53032272017-02-15 An overview of available drugs for management of opioid abuse during pregnancy Laslo, Jillian Brunner, Jon-Michael Burns, Daniel Butler, Emily Cunningham, Autumn Killpack, Ryan Pyeritz, Courtney Rinard, Kimberly Childers, Jennifer Horzempa, Joseph Matern Health Neonatol Perinatol Review The prevalence of opioid abuse in the United States has been steadily increasing over the last several years among many major demographics, including pregnant women. Rise in prenatal opioid abuse has resulted in subsequent escalation of neonatal abstinence syndrome incidence, prompting the US Congress to pass the Protecting Our Infants Act of 2015. This act specifically calls for a critical review of current treatment options for prenatal opioid abuse which may ultimately lead to the development of better therapies and a decreased incidence of neonatal abstinence syndrome. Currently, the American College of Obstetricians and Gynecologists recommends methadone, buprenorphine, or buprenorphine/naloxone in the treatment of prenatal opioid abuse. In this review, each maintenance therapy treatment option is discussed and compared revealing inconsistencies in postpartum retention rates, effects on fetal development, and availability to patients due to restrictions in health care coverage. Although each of these treatment options reduces opioid abuse and potential negative outcomes for the fetus, the shortcomings of these drugs highlight the overarching need for an improved standard of care. Drug developers and lawmakers should consider that affordability, coverage by health insurance, and success in retention rates substantially impacts the decision of the patient and healthcare provider regarding utilization of a particular opioid maintenance therapy. BioMed Central 2017-02-10 /pmc/articles/PMC5303227/ /pubmed/28203387 http://dx.doi.org/10.1186/s40748-017-0044-2 Text en © The Author(s). 2017 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated. |
spellingShingle | Review Laslo, Jillian Brunner, Jon-Michael Burns, Daniel Butler, Emily Cunningham, Autumn Killpack, Ryan Pyeritz, Courtney Rinard, Kimberly Childers, Jennifer Horzempa, Joseph An overview of available drugs for management of opioid abuse during pregnancy |
title | An overview of available drugs for management of opioid abuse during pregnancy |
title_full | An overview of available drugs for management of opioid abuse during pregnancy |
title_fullStr | An overview of available drugs for management of opioid abuse during pregnancy |
title_full_unstemmed | An overview of available drugs for management of opioid abuse during pregnancy |
title_short | An overview of available drugs for management of opioid abuse during pregnancy |
title_sort | overview of available drugs for management of opioid abuse during pregnancy |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5303227/ https://www.ncbi.nlm.nih.gov/pubmed/28203387 http://dx.doi.org/10.1186/s40748-017-0044-2 |
work_keys_str_mv | AT laslojillian anoverviewofavailabledrugsformanagementofopioidabuseduringpregnancy AT brunnerjonmichael anoverviewofavailabledrugsformanagementofopioidabuseduringpregnancy AT burnsdaniel anoverviewofavailabledrugsformanagementofopioidabuseduringpregnancy AT butleremily anoverviewofavailabledrugsformanagementofopioidabuseduringpregnancy AT cunninghamautumn anoverviewofavailabledrugsformanagementofopioidabuseduringpregnancy AT killpackryan anoverviewofavailabledrugsformanagementofopioidabuseduringpregnancy AT pyeritzcourtney anoverviewofavailabledrugsformanagementofopioidabuseduringpregnancy AT rinardkimberly anoverviewofavailabledrugsformanagementofopioidabuseduringpregnancy AT childersjennifer anoverviewofavailabledrugsformanagementofopioidabuseduringpregnancy AT horzempajoseph anoverviewofavailabledrugsformanagementofopioidabuseduringpregnancy AT laslojillian overviewofavailabledrugsformanagementofopioidabuseduringpregnancy AT brunnerjonmichael overviewofavailabledrugsformanagementofopioidabuseduringpregnancy AT burnsdaniel overviewofavailabledrugsformanagementofopioidabuseduringpregnancy AT butleremily overviewofavailabledrugsformanagementofopioidabuseduringpregnancy AT cunninghamautumn overviewofavailabledrugsformanagementofopioidabuseduringpregnancy AT killpackryan overviewofavailabledrugsformanagementofopioidabuseduringpregnancy AT pyeritzcourtney overviewofavailabledrugsformanagementofopioidabuseduringpregnancy AT rinardkimberly overviewofavailabledrugsformanagementofopioidabuseduringpregnancy AT childersjennifer overviewofavailabledrugsformanagementofopioidabuseduringpregnancy AT horzempajoseph overviewofavailabledrugsformanagementofopioidabuseduringpregnancy |